Status:
COMPLETED
Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy
Lead Sponsor:
Southeast Retina Center, Georgia
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Polypoidal Choroidal Vasculopathy
Eligibility:
All Genders
35+ years
Phase:
PHASE1
PHASE2
Brief Summary
This Phase I/II safety study is designed to investigate the safety and efficacy of ranibizumab (Lucentis) in the treatment of polypoidal choroidal vasculopathy (PCV), a potentially blinding eye diseas...
Detailed Description
Please see above description. Phase I/II safety study; prospective, open-label, single-center, non-randomized, uncontrolled, consecutive interventional case series. Enrolled patients are \>35 years ol...
Eligibility Criteria
Inclusion
- Age \>35 years
- Exudative, active PCV in 1 eye.
- PCV is defined as choroidal neovascularization that displays occult characteristics on fluorescein angiography and polypoidal interconnecting vascular channels with saccular dilatations on indocyanine green angiography and/or fluorescein angiography.
Exclusion
- Age \<35 years
- Prior treatment with non-ranibizumab therapies (e.g., laser, surgery, or bevacizumab)
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00837330
Start Date
May 1 2006
End Date
December 1 2010
Last Update
April 16 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Southeast Retina Center
Augusta, Georgia, United States, 30909